Date/Time: March 30, 2016, 2:00pm ET / 12:00 MT
The Dark Issue is the most talked about issue in NBJ history and we’re ready to talk about it some more. Join us March 30 at 2 p.m. eastern standard time for a webinar examining some of the biggest challenges facing the supplement industry. Topics to be discussed include:
The first quarterly webinar of 2016 will feature presentations and discussion with:
The presentations will be followed by what we expect to be a lively Q&A. The Dark Issue webinar is free to subscribers, or with a purchase of the Black Issue Extended Edition. Or buy a seat for $95.
The total number of observations found during cGMP inspections at dietary supplement firms has declined from FY 2014 (the peak was in FY 2013). Production and Process Control (Subpart E) citations continue to dominate, consisting of ~30% of the problems found. In FY 2015, finished product specifications for identity, purity, strength, composition (and for limits on contaminants) remained the most frequent item (as it was in FY 2014) but by a greater margin. Identity testing of components, followed by batch record requirements, continue to top the list of inspectors’ favorite inspection findings.
For those of you who track this stuff, FDA just released new inspections classifications data that can be found at: http://www.fda.gov/ICECI/Inspections/ucm222557.htm
The above chart shows FY2015 inspection classifications in all CFSAN project areas (foods, cosmetics, dietary supplements) and their outcomes (OAI – Official Action Indicated; VAI – Voluntary Action Indicated; NAI – No Action Indicated) OAI and VAI means that a 483 was issued in a particular project area, NAI means basically a clean inspection.
Based on preliminary FY 2015 data released by FDA’s Denver District at the Rocky Mountain Dietary Supplement Forum in Boulder, Colo. last week, Form-483 citations are down overall for dietary supplement firms, and there has been a shift from focusing on identity testing of ingredients (although this is still a very common and important finding) toward observations related to setting specifications for finished products. This trend continues from FY 2014. Data are preliminary because FY 2015 was not yet closed when the data were gathered (closes Sept 30, 2015). I will be publishing complete FY 2015 figures when they become available from FDA’s website. In the meantime, here is a chart based on last week’s data and historical 483 observations from 2009-2014, ordering is based on preliminary FY 2015 frequency.
Note: there are a total of 11 CFR sections listed above (as presented by FDA representatives)
- What aspects of the cGMP are you responsible for during an inspection?
- FDA “Hot buttons” during inspections and what can be done to prepare as well as mitigate
- Detailed analysis of recent (2014-present) FDA inspection reports
- What the inspection reports teach and how to appropriately respond to a Form FDA 483
- Answers to your questions during the Q&A session
- Tony Young, Kleinfeld, Kaplan & Becker/AHPA General Counsel
- Marian Boardley, Marian Boardley Consulting, LLC
- Merle Zimmermann, Ph.D., AHPA
- Jane Wilson, AHPA